Role of colony-stimulating factor in patients receiving myelosuppressive chemotherapy for treatment of cancer

Current Oncology

Volumn 10, Issue 2, 2003, Pages 102-126

  Campbell, Carolyn ^a   Bramwell, V ^b   Charette, M ^b   Oliver, T ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CIPROFLOXACIN; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; KETOCONAZOLE; MESNA; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ADULT; ANAPHYLAXIS; ANEMIA; ASTHENIA; BACKACHE; BIOSAFETY; BONE MARROW SUPPRESSION; BONE PAIN; CARCINOMA; CHILL; CLINICAL TRIAL; DIARRHEA; DYSPEPSIA; ERYTHEMA; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; HEADACHE; HEARTBURN; HUMAN; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; HYPOTENSION; INFECTION; INJECTION PAIN; LETHARGY; LEUKOCYTOSIS; LIMB PAIN; LYMPHOMA; MALAISE; META ANALYSIS; MOUTH INFECTION; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL DISEASE; MYALGIA; MYCOSIS; NAUSEA; NECK PAIN; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PNEUMONIA; PRURITUS; RASH; REVIEW; SENSORY DYSFUNCTION; SEPSIS; SIDE EFFECT; SKIN DISEASE; SOLID TUMOR; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; URTICARIA; VOMITING;

EID: 0344066231     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
2. Rusthoven J, Bramwell V, Stephenson B. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1998;2:179-90.
3. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Eng J Med 1991;325:164-70.
4. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-6.
5. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24.
6. Nguyen Bui B, Chevallier B, Chevreau C, et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13:2629-36.
7. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564-71.
8. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995;13:652-9.
9. Jones SE, Schottstaedt MW, Duncan LA, et al. Randomized double-blind prospective trials to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol 1996;14:2976-83.
10. Muhonen T, Jantunen I, Pertovaara H, et al. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. Am J Clin Oncol 1996;19:232-4.
11. Fridrik MA, Greil R, Hausmaninger H, et al. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austria Working Group for Medical Tumor Therapy. Ann Hematol 1997;75:135-40.
12. Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'étude des lymphomes de l'adulte. Leuk Lymphoma 1997;25:289-300.
13. Negoro S, Masuda N, Furuse K, Saijo N, Fukuoka M. Dose-intensive chemotherapy in extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 1997;40(Suppl):S70-3.
14. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997;89:3974-9.
15. Dunlop DJ, Eatock MM, Paul J, et al. Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol) 1998;10:107-14.
16. Fosså SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716-24.
17. Hidalgo M, Mendiola C, López-Vega JM, et al. A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer 1998;83:719-25.
18. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998;16:642-50.
19. Schröder CP, de Vries EGE, Mulder NH, et al. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor of ciprofloxacin plus amphotericin B. J Antimicrob Chemother 1999;43:741-3.
20. Miles DW, Fogarty O, Ash CM, et al. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994;12:77-82.
21. Gatzemeier U, Kleisbauer JP, Drings P, et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000;23:393-400.
22. Pujol JL, Douillard JY, Rivière A, et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997;15:2082-9.
23. Font A, Moyano AJ, Puerto JM, et al. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer 1999;85:855-63.
24. Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. Jpn J Clin Oncol 1998;28:497-501.
25. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP: a new regimen for advanced Hodgkin's disease. Ann Oncol 1998;9(Suppl 5):S67-71.
26. Masutani M, Tsujino I, Fujie T, et al. Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status? Oncol Rep 1999;6:1045-50.
27. Riccardi A, Tinelli C, Brugnatelli S, et al. Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer. Int J Oncol 2000;16:769-76.
28. Bonomi P, Kim K, Kusler J, Johnson D. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Huntingt) 1997;11 (Suppl 3):9-10.
29. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicenter randomized trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000;18:395-404.
30. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2676-84.
31. Pfreundschuh M, Hasenclever D, Loeffler M, et al. Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF. Ann Oncol 2001;12:471-7.
32. Del Mastro L, Venturini M, Lionetto R, et al. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Oest-Mammella Inter Gruppo Group. J Clin Oncol 2001;19:2213-21.
33. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001;19:1088-95.
34. Sternberg CN, de Mulder PHM, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 2001;19:2638-46.
35. Cella D, Fairclough DL, Bonomi PB, Kim K, Johnson D. Quality of life (QOL) in advanced non-small cell lung cancer (NSCLC): results from Eastern Cooperative Oncology Group (ECOG) study E5592 [abstract 4]. Proc Am Soc Clin Oncol 1997;16:2a.
36. Mayordomo JI, Rivera F, Díaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;87:803-8.
37. Ravaud A, Chevreau C, Cany L, et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol 1998;16:2930-6.
38. Arnberg H, Letocha H, Nõu F, Westlin J, Nilsson S. GM-CSF in chemotherapy - induced febrile neutropoenia-a double-blind randomized study. Anticancer Res 1998;18:1255-60.
39. García-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31-8.
40. Anaissie EJ, Vartivarian S, Bodey GP, et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia. Am J Med 1996;100:17-23.
41. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:492-501.
42. Biesma B, de Vries EGE, Willemse PHB, et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 1990;26:932-6.
43. Torrecillas L, Cervantes G, Zamora R, et al. GM-CSF discontinuation safe level for patients with chemotherapy induced febrile or afebrile neutropenia [abstract 304]. Proc Am Soc Clin Oncol 1998;17:79a.
44. Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996;14:619-27.
45. Beveridge RA, Miller JA, Kales AN, et al. A comparison of efficacy of sargramostim (yeast-derived rHUGM-CSF) and filgrastim (bacteria-derived rHUG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 1998;16:366-73.
46. Regan DH, Camp K, Cygnarowicz P, Dirolf J. Prospective study to evaluate CSF use for primary and secondary prevention of chemotherapy-induced neutropenia [abstract 2336]. Proc Am Soc Clin Oncol 1999;18:605a.
47. Mustacchi G, Ceccherini R, Milani S, Sandri P, Leita ML, Carbonara T. Effectiveness of sequential administration of G-CSF and GM-CSF after antineoplastic chemotherapy in patients with advanced tumors: results of a randomized trial [Italian]. Tumori 1997;83(Suppl):S13-16.
48. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31.
49. Soda H, Oka M, Fukuda M, et al. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Cancer Chemother Pharmacol 1996;38:9-12.
50. Higa GM, DeVore RF, Auber ML, Lynch JP, Landreth KS. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration. Pharmacotherapy 1998;18:1-8.
51. Crawford J, Kreisman H, Garewal H, et al. The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 1997;8:1117-24.
52. Stöger H, Samonigg H, Krainer M, et al. Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor. Eur J Cancer 1998;34:482-8.
53. Langer CJ. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999;9(Suppl 1):108-16.
54. Kobrinsky NL, Sjolander DE, Cheang MS, Levitt R, Steen PD. Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early-stage breast cancer. J Clin Oncol 1999;17:3426-30.
55. Oshita F, Yamada K, Nomura I, et al. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer. Am J Clin Oncol 2000;23:278-82.
56. Aglietta M, Montemurro F, Fagioli F, et al. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. Cancer 2000;88:454-60.
57. Juan O, Campos JM, Carañana V, Sanchez JJ, Casañ R, Alberola V. A randomized, crossover comparison of standard-dose (SD) versus low-dose (LD) lenograstim (LEN) in the prophylaxis on post-chemotherapy neutropenia [abstract 2503]. Proc Am Soc Clin Oncol 2000;19:634a.
58. Dinçol D, Samur M, Pamir A, et al. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. Cancer 2000;88:2033-6.
59. Fukuda M, Nakano M, Kinoshita A, et al. Optimal timing of G-CSF administration in patients receiving chemotherapy for non-small cell lung cancer (NSCLC) [abstract 1549]. Proc Am Soc Clin Oncol 1993;12:447.
60. Hamm J, Schiller JH, Cuffie C, et al. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol 1994;12:2667-76.
61. Gerhartz HH, Stern AC, Wolf-Hornung B, et al. Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy. Leuk Res 1993;17:175-85.
62. Janik JE, Miller LL, Kom EL, et al. A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naïve patients with malignant melanoma or renal cell carcinoma. Blood 2001;97:1942-6.
63. Karthaus M, Rosenthal C, Huebner G, et al. Effect of topical G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-5.
64. Hejna M, Kostler W, Raderer M, et al. A prospective randomized trial on the efficacy in GM-CSF mouthwashes for the treatment of chemotherapy-induced oral mucositis [abstract 2407]. Proc Am Soc Clin Oncol 2000;19:611a.
65. Crawford J, Tomita DK, Manzanet R, Glaspy J, Ozer H. Reduction of oral mucositis by filgrastim (r-metHUG-CSF) in patients receiving chemotherapy. Cytokines Cell Mol Ther 1999;5:187-93.
66. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85.
67. Ontario, Ministry of Health and Long-Term Care, Ontario Drug Benefit. Guidelines for coverage of Neupogen (filgrastim or G-CSF) through the Section 8 (individual request) process. May 1996.
68. Glaspy JA, Bleecker G, Crawford J, Stoller R, Strauss M. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993;29A(Suppl 7): S23-30.
69. Uyl-de Groot CA, Vellenga E, Rutten FF. An economic model to assess the savings from a clinical application of haematopoietic growth factors. Eur J Cancer 1996;32A:57-62.
70. Chouaid C, Bassinet L, Fuhrman C, Monnet I, Housset B. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998;16:2700-7.
71. Silber JH, Fridman M, Shpilsky A, et al. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998;16:2435-44.
72. Messori A, Trippoli S, Tendi E. c-csF G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J Clin Pharm Ther 1996;21:57-63.
73. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857-64.
74. O'Brien BJ, Goeree R, Gafni A, et al. Assessing the value of a new pharmaceutical: a feasibility study of contingent valuation in managed care. Med Care 1998;36:370-84.
75. Bennett CL, Stinson TJ, Bhoopalam N, et al. A double-blind, randomized trial of toxicity, resource use and costs for filgrastim and sargramostim [abstract 1712]. Proc Am Soc Clin Oncol 2000;19:437a.
76. Bernstein BJ, Blanchard LM. Economic and clinical impact of a pharmacy-based filgrastim protocol in oncology patients. Am J Health Syst Pharm 1999;56:1330-3. [Erratum in: Am J Health Syst Pharm 2000;57:392]
77. Bernstein BJ, Blanchard LM. Economic and clinical impact of a pharmacy-based filgrastim protocol in oncology patients. Am J Health Syst Pharm 1999;56:1330-3. [Erratum in: Am J Health Syst Pharm 2000;57:392]